$3.23 -0.3 -7.7%
Last Trade - 25/02/21
| Market Cap | ÂŁ105.1m |
| Enterprise Value | ÂŁ94.6m |
| Revenue | ÂŁn/a |
| Position in Universe | 4686th / 6709 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 14.4 | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | April 2, 2003 |
| Public Since | January 30, 2007 |
| No. of Shareholders: | n/a |
| No. of Employees: | 48 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market (Dual Listing) |
| Shares in Issue | 42,459,479 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Modi'in Technology Park,2 HaMa'ayan Street, MODIIN, 7177871, Israel |
| Web | http://www.biolinerx.com |
| Phone | +972 8 6429100 |
| Contact | () |
| Auditors | Kesselman & Kesselman |
As of 25/02/21, shares in BioLine RX are trading at $3.23, giving the company a market capitalisation of ÂŁ105.1m. This share price information is delayed by 15 minutes.
Shares in BioLine RX are currently trading at $3.23 and the price has moved by 85.19% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioLine RX price has moved by 48.69% over the past year.
Of the analysts with advisory recommendations for BioLine RX, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioLine RX is Buy. You can view the full broker recommendation list by unlocking its StockReport.
BioLine RX is scheduled to issue upcoming financial results on the following dates:
BioLine RX does not currently pay a dividend.
BioLine RX does not currently pay a dividend.
BioLine RX does not currently pay a dividend.
To buy shares in BioLine RX you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in BioLine RX are currently trading at $3.23, giving the company a market capitalisation of ÂŁ105.1m.
Here are the trading details for BioLine RX:
Based on an overall assessment of its quality, value and momentum, BioLine RX is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in BioLine RX are currently priced at $3.23. At that level they are trading at 1.56% discount to the analyst consensus target price of 0.00.
Analysts covering BioLine RX currently have a consensus Earnings Per Share (EPS) forecast of -20.6769386379 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioLine RX. Over the past six months, the relative strength of its shares against the market has been 66.13%. At the current price of $3.23, shares in BioLine RX are trading at 61.42% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for BioLine RX.
BioLine RX's management team is headed by:
Here are the top five shareholders of BioLine RX based on the size of their shareholding:
